US2016067360A1PendingUtilityA1

Modulators of pharmacokinetic properties of therapeutics

Assignee: GILEAD SCIENCES INCPriority: Jul 7, 2006Filed: Aug 17, 2015Published: Mar 10, 2016
Est. expiryJul 7, 2026(expired)· nominal 20-yr term from priority
A61P 31/18A61P 31/14A61P 31/12A61P 31/00A61P 43/00A61P 7/00C07C 315/04C07C 227/18C07D 277/28C07C 227/16C07D 417/14C07D 277/24C07C 209/78A61K 31/5377A61K 31/4402A61K 31/426A61K 45/06A61K 38/005A61K 45/00C07D 277/30A61K 38/05C07K 5/06034C07D 417/12C07K 5/06052A61K 31/496A61K 31/427C07K 5/06A61K 31/4535A61K 31/47C07K 5/06026A61K 51/0453
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 : A diagnostic assay for determining a therapeutic dose in a mammal of a compound of formula IB: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein, 
         L 2  is a covalent bond, —C(R 6 ) 2 — or —C(O)—; 
         Z 1  is —O— or —N(R 7 )—; 
         R 6  is selected from the group consisting of H, alkyl, substituted alkyl, and heteroalkyl; 
         R 7  is selected from the group consisting of H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, and substituted heterocyclyl; and 
         R 8  and R 9  are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, and —CN; 
         the diagnostic assay comprising 
         a) administering to the mammal a radiolabeled compound of formula IB, 
         b) measuring the quantity of a metabolic product of the radiolabeled compound of formula IB; and 
         c) determining the therapeutic dose of a compound of formula IB for the mammal. 
       
     
     
         22 : The diagnostic assay of  claim 21 , wherein the radiolabeled compound of Formula IB comprises C 14 . 
     
     
         23 : The diagnostic assay of  claim 21 , wherein the radiolabeled compound of formula IB comprises H 3 . 
     
     
         24 : The diagnostic assay of  claim 21 , wherein the metabolic product results from a physiological pathway selected from the group consisting of oxidation, reduction, hydrolysis, amidation, and esterification.

Join the waitlist — get patent alerts

Track US2016067360A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.